Shares of Idexx Laboratories Inc. (NASDAQ:IDXX) rose 88 centson Wednesday to $24 after Oppenheimer & Co. analyst GlennReicin told his firm's sales force that he rated the Westbrook,Maine, company a "buy."
"Idexx is one of the few companies in the $12 billiondiagnostics industry that we believe is worthy of investment,"Reicin wrote in his forthcoming report. "It has a dominantmarket share that we believe is sustainable in its corebusinesses for animal health and food quality assurance."
Reicin foresees annual revenue growth of more than 30 percentfor the next three to five years and expects the stock to moveinto the $30-to-$35 range over the next six months.
(c) 1997 American Health Consultants. All rights reserved.